It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.
This is a significant milestone for Psyence Therapeutics as it signals the start of our drug development process. The next step is to commence our engagement with the Medicines and Healthcare products Regulatory Authority in order to get approval to commence our clinical trial in the context of palliative care.